With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the ...

With Incyte losing patent protection for blood cancer standout Jakafi in late 2028, the Delaware-based company will have to rely more on its topical cream Opzelura. | With Incyte set to lose patent ...

As the U.S. backpedals on its mRNA investment, Mexico is embracing the technology through a new manufacturing pact with Moderna to produce vaccines domestically.  | The agreement includes mRNA vaccine ...

After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030” revenue target, outlining a roadmap to have more than 25 blockbuster ...

Breast cancer drug Kisqali outperformed its 2025 sales target by 9%, while a portfolio of recent launches that includes radioligand therapy Pluvicto, kidney disease drugs Fabhalta and Vanrafia, and ...

Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new ...

With online health and wellness company Hims & Hers opening a new front in the GLP-1 compounding showdown Thursday, the ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...

The campaign highlights the crossover that Lilly sees between its own 150 years of working toward scientific progress and the ...

On the branded side of things, Sun’s skin cancer offerings include Odomzo for basal cell carcinoma and Unloxcyt, an ...

Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said ...

All together, the initiative is meant to help HCPs “better understand the full lived experience of ADHD, including its impact on school or work performance, relationships and self-esteem,” according ...